Does Blue Cross Blue Shield of North Carolina Cover Ozempic?

What Ozempic Is and Why the Indication Matters for Coverage

Ozempic is a once-weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist containing semaglutide at doses of 0.5 mg, 1 mg, and 2 mg. The FDA approved semaglutide for type 2 diabetes in December 2017 and later expanded the label in 2020 to include reduction of major adverse cardiovascular events in adults with T2D and established cardiovascular disease. 1

Semaglutide works by mimicking endogenous GLP-1, which stimulates glucose-dependent insulin release, suppresses glucagon, and slows gastric emptying. 2 These mechanisms produce both glycemic control and, as a secondary effect, body-weight reduction, which is why patients and prescribers sometimes request Ozempic off-label for obesity. That off-label use is the core reason BCBS NC and most insurers attach strict prior authorization criteria: the FDA has approved a separate semaglutide product (Wegovy, semaglutide 2.4 mg) specifically for chronic weight management, so payers redirect obesity-only requests there. 3

The SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide 0.5 mg and 1 mg reduced the composite of cardiovascular death, nonfatal MI, and nonfatal stroke by 26% versus placebo (HR 0.74; 95% CI 0.58, 0.95; P<0.001 for non-inferiority, P=0.02 for superiority) in patients with T2D and high cardiovascular risk. 4 That cardiovascular outcome data strengthened payer justification for covering Ozempic in the T2D population with established CVD.

The SUSTAIN-7 trial (N=1,201) compared semaglutide 0.5 mg and 1 mg head-to-head against dulaglutide 0.75 mg and 1.5 mg. Semaglutide 1 mg produced a mean A1c reduction of 1.8 percentage points versus 1.4 percentage points for dulaglutide 1.5 mg at 40 weeks (P<0.001). 5 This comparative efficacy data matters for coverage appeals when step therapy has been completed.

How BCBS NC Organizes Its Formularies

BCBS NC administers several distinct plan types in North Carolina, each with its own drug formulary. The main categories are:

Commercial employer-sponsored plans. Large-group and small-group plans negotiated through employers. Ozempic typically lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on the specific employer benefit design. Tier 3 cost-sharing often runs $60, $100 per 30-day supply after deductible; Tier 4 can reach $150, $200 or higher. 6

ACA Marketplace (Blue options) plans. These follow the same core formulary logic but must comply with Affordable Care Act essential health benefit rules. Specialty medications, including some GLP-1 agonists, may face separate specialty deductibles.

North Carolina State Health Plan. Covers state employees and teachers. The State Health Plan formulary is updated annually; as of the 2024 to 2025 plan year, Ozempic requires prior authorization with documented T2D diagnosis and A1c data.

Medicare Advantage and Medicare Part D plans. BCBS NC administers several Medicare products. Under Part D, the 2024 Medicare Drug Price Negotiation Program began a separate pathway, but Ozempic was not among the first ten drugs selected for negotiation under the Inflation Reduction Act. 7 Medicare Advantage formulary placement varies by contract year.

Prior Authorization Criteria: What BCBS NC Typically Requires

Prior authorization for Ozempic at BCBS NC generally requires the prescriber to document several items simultaneously. Exact criteria vary by plan variant and may change at each January 1 formulary refresh, so confirming with BCBS NC member services (1-800-446-8053 for most commercial plans) before prescribing is necessary.

Standard documentation typically required:

1. Confirmed diagnosis of type 2 diabetes mellitus (ICD-10 E11.x), not type 1 (E10.x) or prediabetes (R73.09).
2. A recent hemoglobin A1c result, commonly A1c >7.0% or >8.0% depending on plan tier rules.
3. Documentation of concurrent or prior use of metformin (unless contraindicated due to renal impairment, GFR <30 mL/min/1.73m², or documented intolerance).
4. Step therapy: at least one prior antidiabetic agent tried, such as a sulfonylurea, SGLT-2 inhibitor, or DPP-4 inhibitor, unless a clinical exception applies.
5. Prescriber attestation that Ozempic is being used for glycemic control, not for weight loss alone.
6. Current body weight and BMI are sometimes requested to rule out obesity-only prescribing.

The American Diabetes Association's 2024 Standards of Care in Diabetes support GLP-1 receptor agonists as preferred add-on therapy for patients with T2D and atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, listing semaglutide among agents with the strongest evidence. 8

The American Association of Clinical Endocrinology (AACE) 2022 Clinical Practice Guideline similarly recommends GLP-1 RAs as a first-line injectable option when A1c remains above goal on oral agents, specifically naming semaglutide as a high-evidence recommendation. 9

Step Therapy: Which Drugs Must You Try First

Most BCBS NC commercial plans invoke step therapy before approving Ozempic. Step therapy means the patient must have documented use of a less expensive agent first.

Metformin is almost universally the required first step. The American Diabetes Association notes that metformin remains the preferred initial pharmacotherapy for T2D when tolerated, given its efficacy, safety record, and low cost. 10 If metformin is contraindicated due to renal impairment (eGFR <30 mL/min/1.73m²) or causes persistent gastrointestinal intolerance, the prescriber can document a contraindication exception.

After metformin, some plans require a second oral agent. Common options accepted as satisfying step therapy include:

• Glipizide or glimepiride (sulfonylureas, Tier 1 on most formularies)
• Sitagliptin (Januvia) or alogliptin (DPP-4 inhibitors, Tier 2 on most plans)
• Empagliflozin (Jardiance) or dapagliflozin (Farxiga) (SGLT-2 inhibitors, though these may themselves require prior authorization on some plans)

If the patient has established cardiovascular disease or heart failure, prescribers can invoke the ADA/AACE guidance to bypass standard step therapy and request a cardiovascular-indication exception. The PIONEER 6 trial data on oral semaglutide and the SUSTAIN-6 injectable data both support this pathway. 11

What to Do if BCBS NC Denies Ozempic Coverage

Denial does not mean no coverage exists. The appeals process is a defined legal right under the ACA and ERISA for employer plans. A structured appeal frequently succeeds.

Step 1: Request the denial letter and Explanation of Benefits (EOB). The denial letter must state the specific coverage criterion not met and cite the plan language. Read it carefully before crafting the appeal.

Step 2: File a formal internal appeal within the timeframe stated. Most BCBS NC plans allow 180 days from the denial date for internal appeals. The appeal should include:

• A letter of medical necessity from the prescribing physician citing the ADA 2024 Standards of Care recommendation for GLP-1 RAs in T2D with cardiovascular risk 8
• Documentation of all prior drug trials
• A1c results pre- and post-prior therapy to show inadequate glycemic control
• Any evidence of cardiovascular disease, heart failure, or chronic kidney disease that supports preferred-agent designation

Step 3: Request an expedited appeal if the standard timeline creates clinical risk. Urgent appeals must be decided within 72 hours.

Step 4: External appeal. If the internal appeal fails, North Carolina law allows an external independent review. The North Carolina Department of Insurance oversees this process under NCGS Chapter 58, Article 50. 12

The SUSTAIN-8 trial (N=1,089) showed semaglutide 1 mg reduced A1c by 1.5 percentage points more than canagliflozin 300 mg at 52 weeks (P<0.001), evidence useful in step-therapy exception requests when an SGLT-2 was tried and proved insufficient. 13

Cost Without Coverage: List Price, Generics, and Assistance Programs

If prior authorization fails or the plan excludes Ozempic entirely, patients face the list price. As of mid-2025, a 4-dose (1 month) Ozempic pen carries a Wholesale Acquisition Cost near $935. 14

Several cost-reduction pathways exist:

Novo Nordisk patient assistance. The Novo Nordisk Patient Assistance Program (1-866-310-7549) provides Ozempic free of charge to uninsured or underinsured patients with household income at or below 400% of the federal poverty level. 15

Ozempic savings card. Commercially insured patients who are eligible (not on a government program) may pay as little as $25 per month for up to 24 months via the Novo Nordisk savings card. Eligibility requires commercial insurance that covers Ozempic but with high out-of-pocket cost. 16

GoodRx and pharmacy discount programs. GoodRx and similar discount platforms can reduce the cash price to approximately $800, $870 at major North Carolina pharmacies, which does not beat the savings card for eligible patients but provides a baseline for uninsured patients.

Compounded semaglutide. The FDA has placed semaglutide on the 503B outsourcing facility shortage list in prior years due to supply constraints. However, the FDA formally removed semaglutide from the shortage list in March 2025, which means compounded semaglutide from 503A pharmacies is no longer legally permitted for most patients as of that date. 17 Patients should confirm current FDA shortage status before pursuing this route, as the regulatory picture can shift.

Ozempic vs. Wegovy: Why BCBS NC Treats Them Differently

Both Ozempic and Wegovy contain semaglutide, but they carry distinct FDA approvals, National Drug Codes, and formulary designations.

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved for T2D and cardiovascular risk reduction. 1

Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with BMI >30 kg/m², or BMI >27 kg/m² with at least one weight-related comorbidity. 3

In the STEP-1 trial (N=1,961), Wegovy produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001). 18 BCBS NC plans that cover anti-obesity medications route those requests to Wegovy, not Ozempic. Many employer-sponsored BCBS NC plans currently exclude anti-obesity medications entirely, meaning Wegovy coverage is also not guaranteed even for eligible patients.

Prescribing Ozempic solely for weight loss in a patient without T2D creates a payer conflict: BCBS NC will deny the claim on the grounds that the FDA-approved weight-management form (Wegovy) should be used, and if that is also excluded, coverage does not exist under either brand. Patients need a documented T2D diagnosis for Ozempic to be approvable.

A1c Thresholds and Clinical Monitoring Requirements

BCBS NC prior authorization criteria typically specify that the patient's A1c must exceed a stated value at the time of the PA request. The most common thresholds seen across commercial plan variants are A1c >7.0% for standard add-on therapy and A1c >8.0% when the plan applies stricter criteria for newer agents.

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and atherosclerotic cardiovascular disease, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended as part of the glucose-lowering regimen, independent of A1c level." 8 This language is directly relevant for PA exceptions: if a prescriber documents cardiovascular disease, the A1c threshold may not apply.

Ongoing coverage renewals (reauthorization, typically every 12 months) generally require evidence of clinical benefit. BCBS NC may request a follow-up A1c showing at least a 0.5, 1.0 percentage point reduction to justify continued coverage. In the SUSTAIN-1 trial (N=388), semaglutide 0.5 mg reduced A1c by 1.5 percentage points and semaglutide 1 mg by 1.6 percentage points at 30 weeks versus no change with placebo. 19 Documenting this degree of response from the patient's first covered prescription strengthens the reauthorization submission considerably.

How to Submit a Prior Authorization for Ozempic at BCBS NC

Prescribers and their office staff initiate the PA through one of three channels:

1. NaviHealth / AIM Specialty Health portal. BCBS NC uses AIM Specialty Health for many specialty drug prior authorizations. Prescribers log in at aimspecialtyhealth.com and select "pharmacy" PA.
2. Availity portal. The Availity Essentials platform accepts PA submissions for BCBS NC. The prescriber or authorized staff selects the member, chooses the drug (semaglutide/Ozempic, NDC 00169-4060-12 for the 2 mg/3 mL pen or the applicable NDC for the prescribed dose), and attaches clinical documentation.
3. Fax. BCBS NC also accepts faxed PA requests. The standard BCBS NC Pharmacy PA fax number for commercial plans is 1-888-333-7071, though this should be confirmed for the specific plan.

Turnaround for standard PA decisions is 3, 5 business days. Urgent/expedited requests must be decided within 24 to 72 hours. The prescriber should document the clinical urgency explicitly in the request to qualify for expedited review.

The FDA drug label for Ozempic provides full prescribing information including boxed warning for thyroid C-cell tumor risk (based on rodent data; relevance to humans unknown), which should be disclosed to patients and documented. 1

Renal and Hepatic Considerations That Affect PA Documentation

Semaglutide does not require dose adjustment for renal impairment, an advantage over metformin (contraindicated when eGFR <30). The FDA label states no dose adjustment is needed for any stage of chronic kidney disease. 1 When documenting a metformin contraindication due to renal impairment, the prescriber should include the most recent serum creatinine and calculated eGFR in the PA submission.

The FLOW trial (N=3,533), published in 2024 in the New England Journal of Medicine, found semaglutide 1 mg reduced the composite of major kidney disease events by 24% versus placebo (HR 0.76; 95% CI 0.66, 0.88; P<0.001) in patients with T2D and chronic kidney disease. 20 Including this data in a PA for a patient with both T2D and CKD substantially strengthens the medical necessity argument.

Hepatic impairment does not require dose adjustment either, though the PA form may ask about liver disease because NAFLD/NASH is common in the T2D population. The prescriber can simply note "hepatic impairment present; no dose adjustment required per FDA labeling."

What North Carolina State Law Says About Step Therapy

North Carolina enacted step therapy reform legislation (Session Law 2019-202) that limits how health plans can apply step therapy for patients already stabilized on a medication. 21 The law requires insurers to grant a step therapy override when:

• The patient has already tried and failed the required step therapy drugs.
• The required step therapy drug is contraindicated or would cause adverse effects.
• The patient is currently stable on the requested medication and changing would cause clinical instability.
• The required step drug is not clinically effective based on the patient's history.

This state law applies to fully insured commercial plans regulated by the North Carolina Department of Insurance. Self-funded employer plans governed by ERISA are preempted from state insurance law, so step therapy override protections may not apply to every BCBS NC plan. The prescriber should verify whether the patient's plan is fully insured or self-funded to determine which protections apply.

Key Timelines and Practical Checklist for Patients and Prescribers

Patients starting the prior authorization process should expect the following timeline:

• Day 1: Prescriber submits PA with complete documentation.
• Days 3, 5: Standard PA decision rendered. If approved, prescription goes to pharmacy.
• Days 5, 10: If denied, denial letter arrives by mail or portal. Appeal clock starts.
• Days 10, 60: Internal appeal filed, reviewed, and decided (up to 60 days for non-urgent internal appeals).
• Days 60+: External review filed if internal appeal fails.

A practical documentation checklist for the prescriber's PA submission:

• ICD-10 diagnosis code (E11.x for T2D)
• Most recent A1c with date of test
• Current medications with start and stop dates
• Documented contraindications to step therapy agents if applicable
• Cardiovascular disease history (ICD-10 I25.x for CAD, I50.x for heart failure, etc.)
• eGFR if metformin contraindication is claimed
• Prescribing physician NPI and DEA number
• Patient insurance ID and group number

The FDA label notes Ozempic is administered once weekly, on the same day each week, with or without meals. 1 Documenting the once-weekly dosing schedule in the PA confirms the medication is being used per label, not at off-label weight-loss doses.